Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Patient dies in Bristol Myers Squibb autoimmune CAR-T trial" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include WSJ. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 24d ago.
Quick answers
Why is "Patient dies in Bristol Myers Squibb autoimmune CAR-T trial" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Should Patient Death Disclosure Require Action From Bristol Myers Squibb (BMY) Investors? Simply Wall Street · 24d ago
- BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial BioSpace · 24d ago
- Bristol-Myers Says After Breakfree-2 Study Data Cutoff, One haRMS Patient Experienced A Fatal Event Of Septic Pneumonia TradingView · 24d ago
- Q&A: Bristol Myers’ Lynelle Hoch on autoimmune CAR-T safety challenges, MS patient death Endpoints News · 24d ago
- Patient Death Reported in Bristol Myers Squibb Autoimmune Study WSJ · 24d ago
Topics
Related trends
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
How Maya Jama went from Bristol native to Celebrity Traitors star
Maya Jama garners widespread praise for a generous charity donation following a high-stakes betrayal in the finale of Celebrity Traitors.
Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
Caribou Biosciences, a biotech firm co-founded by Nobel laureate Jennifer Doudna, is halting its pipeline and reducing staff amid potential closure.
Kenya’s First Ebola Patient Flew To Nairobi Two Days Before He Died
Kenya confirms its first-ever Ebola case and death, triggering quarantines and exposing border screening gaps.
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
Adicet Bio's experimental CAR-T therapy sparks early lupus remissions, drawing widespread industry attention.
Carson Hocevar, Ryan Blaney trade niceties a week after Bristol fight
Carson Hocevar and Ryan Blaney trade niceties following their widely covered Bristol Motor Speedway brawl.